Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia

Genome variability of host genome and cancer cells play critical role in diversity of response to existing therapies and overall success in treating oncological diseases. In chronic myeloid leukemia targeted therapy with tyrosine kinase inhibitors demonstrates high efficacy in most of the patients.